Day: June 29, 2023

VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2023 annual general meeting of shareholders held on June 28, 2023 (the “Meeting”). All four members of the Company’s board of directors named as nominees in its management information circular (the “Circular”) were re-elected as directors: Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia and Michael Liggett. Additional voting results from the Meeting include: (i) the shareholders approved the appointment of Davidson & Company LLP as the Company’s auditor until the next annual meeting; and (ii) the shareholders approved the Company’s...

Achievement attests to quality, reliability and repeatability of Weebit’s embedded IP for use in customer production chips HOD HASHARON, Israel and BLOOMINGTON, Minn., June 28, 2023 (GLOBE NEWSWIRE) — Weebit Nano Limited (ASX:WBT), a leading developer of advanced memory technologies for the global semiconductor industry, and SkyWater Technology (NASDAQ: SKYT), the trusted technology realization partner, confirm Weebit Resistive Random-Access Memory (ReRAM) IP has been fully qualified for industrial temperatures employing SkyWater’s 130nm CMOS (S130) process, including third party processing. The full qualification confirms the quality, repeatability and reliability of Weebit’s embedded ReRAM module, when SkyWater customers use Weebit’s proven non-volatile memory (NVM) IP in volume production. The qualification used demo chips produced...

Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an effective treatment in patients with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP) Advisory committee further voted 11 for and 3 against on the benefits of palovarotene outweighing the risks, for the treatment of patients with FOP FDA PDUFA action date is anticipated by August 16, 2023PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effective treatment, with a positive risk-benefit profile, for people living with the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). The FDA is currently...